Cargando…

Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been approved for the treatment of metastatic renal cell carcinoma (mRCC). However, the response rate is still limited, and it is urgent to pursue novel and concise markers of responses to ICIs that allow the determination of clinical benefits. Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumura, Soichi, Kato, Taigo, Kujime, Yuma, Kitakaze, Hiroaki, Nakano, Kosuke, Hongo, Sachiko, Yoshioka, Iwao, Okumi, Masayoshi, Nonomura, Norio, Takada, Shingo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257831/ https://www.ncbi.nlm.nih.gov/pubmed/37301837 http://dx.doi.org/10.1186/s12894-023-01248-z

Ejemplares similares

Multimodal therapy including robot‐assisted radical cystoprostatectomy for locally advanced prostate cancer with bladder and ureteral invasion: A case report
por: Okumi, Masayoshi, et al.
Publicado: (2022)

Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report
por: Kojima, Yasuyuki, et al.
Publicado: (2015)

Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience
por: Kato, Taigo, et al.
Publicado: (2015)

The benefits of cancer screening in kidney transplant recipients: a single‐center experience
por: Kato, Taigo, et al.
Publicado: (2015)

Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma
por: Nishimura, Yuki, et al.
Publicado: (2022)

Depression of Complement Regulatory Factors in Rat and Human Renal Grafts Is Associated with the Progress of Acute T-Cell Mediated Rejection
por: Yamanaka, Kazuaki, et al.
Publicado: (2016)

Clinical Efficacy of Intravenous Immunoglobulin for BK Polyomavirus-Associated Nephropathy After Living Kidney Transplantation
por: Matsumura, Soichi, et al.
Publicado: (2020)

Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study
por: Inoue, Yuta, et al.
Publicado: (2023)

Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Koh, Yoko, et al.
Publicado: (2022)

Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report
por: Mizutani, Kosuke, et al.
Publicado: (2017)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
por: Hatano, Koji, et al.
Publicado: (2023)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration‐resistant prostate cancer
por: Fujita, Kazutoshi, et al.
Publicado: (2020)

Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
por: Okamoto, Takeshi, et al.
Publicado: (2021)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

Drug‐induced interstitial pneumonia after intravesical Bacillus Calmette‐Guerin administration for bladder cancer with scleroderma
por: Yoshioka, Fumie, et al.
Publicado: (2023)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma
por: Narukawa, Tsukasa, et al.
Publicado: (2020)

Diagnostic and prognostic significance of tartrate‐resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real‐world multi‐institutional study
por: Yamamichi, Gaku, et al.
Publicado: (2022)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

A case of thoracic SMARCA4‐Deficient undifferentiated tumor successfully treated with combination Ipilimumab–Nivolumab
por: Nakano, Yoshio, et al.
Publicado: (2022)

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
por: Teishima, Jun, et al.
Publicado: (2023)

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
por: Takada, Masahiro, et al.
Publicado: (2022)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Minohara, Kiyoshi, et al.
Publicado: (2021)

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
por: Paoluzzi, L., et al.
Publicado: (2016)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
por: D’Angelo, Sandra P., et al.
Publicado: (2022)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021)

Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
por: Numakura, Kazuyuki, et al.
Publicado: (2023)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
por: Sadagopan, Narayanan, et al.
Publicado: (2019)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fqripc4qdg511aanf0ikhd5a2d